JP2024538694A - シクロペンチルピラゾールｃｄｋ２阻害剤 - Google Patents
シクロペンチルピラゾールｃｄｋ２阻害剤 Download PDFInfo
- Publication number
- JP2024538694A JP2024538694A JP2024520826A JP2024520826A JP2024538694A JP 2024538694 A JP2024538694 A JP 2024538694A JP 2024520826 A JP2024520826 A JP 2024520826A JP 2024520826 A JP2024520826 A JP 2024520826A JP 2024538694 A JP2024538694 A JP 2024538694A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharma
- ring
- acceptable salt
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252394P | 2021-10-05 | 2021-10-05 | |
| US63/252,394 | 2021-10-05 | ||
| PCT/US2022/077501 WO2023060057A1 (en) | 2021-10-05 | 2022-10-04 | Cyclopentylpyrazole cdk2 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024538694A true JP2024538694A (ja) | 2024-10-23 |
| JP2024538694A5 JP2024538694A5 (https=) | 2025-10-10 |
| JPWO2023060057A5 JPWO2023060057A5 (https=) | 2025-10-10 |
Family
ID=84245758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520826A Pending JP2024538694A (ja) | 2021-10-05 | 2022-10-04 | シクロペンチルピラゾールｃｄｋ２阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240425478A1 (https=) |
| EP (1) | EP4412995A1 (https=) |
| JP (1) | JP2024538694A (https=) |
| KR (1) | KR20240077491A (https=) |
| CN (1) | CN118019734A (https=) |
| AR (1) | AR127247A1 (https=) |
| AU (1) | AU2022360968A1 (https=) |
| CA (1) | CA3229067A1 (https=) |
| TW (1) | TW202330501A (https=) |
| WO (1) | WO2023060057A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| CN119072471A (zh) * | 2022-04-28 | 2024-12-03 | 正大天晴药业集团股份有限公司 | 一种吡唑取代环戊酯衍生物及其用途 |
| CN120239698A (zh) * | 2022-11-17 | 2025-07-01 | 山东绿叶制药有限公司 | Cdk2抑制剂及其制备方法和应用 |
| WO2025136671A1 (en) * | 2023-12-20 | 2025-06-26 | Ensem Therapeutics, Inc. | Anilino-pyrazole derivatives, compositions and methods thereof |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113330000B (zh) * | 2019-01-31 | 2024-12-24 | 辉瑞公司 | 具有对cdk2的抑制活性的3-羰基氨基-5-环戊基-1fi-吡咯化合物 |
| CN110536068B (zh) | 2019-09-29 | 2021-09-28 | Oppo广东移动通信有限公司 | 对焦方法和装置、电子设备、计算机可读存储介质 |
| TW202246255A (zh) * | 2021-02-12 | 2022-12-01 | 美商傳達治療有限公司 | Ｃｄｋ抑制劑及其使用方法 |
-
2022
- 2022-10-04 AU AU2022360968A patent/AU2022360968A1/en active Pending
- 2022-10-04 TW TW111137712A patent/TW202330501A/zh unknown
- 2022-10-04 CA CA3229067A patent/CA3229067A1/en active Pending
- 2022-10-04 US US18/698,664 patent/US20240425478A1/en active Pending
- 2022-10-04 WO PCT/US2022/077501 patent/WO2023060057A1/en not_active Ceased
- 2022-10-04 KR KR1020247011084A patent/KR20240077491A/ko active Pending
- 2022-10-04 AR ARP220102682A patent/AR127247A1/es unknown
- 2022-10-04 JP JP2024520826A patent/JP2024538694A/ja active Pending
- 2022-10-04 CN CN202280065852.1A patent/CN118019734A/zh active Pending
- 2022-10-04 EP EP22800510.4A patent/EP4412995A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR127247A1 (es) | 2024-01-03 |
| US20240425478A1 (en) | 2024-12-26 |
| WO2023060057A1 (en) | 2023-04-13 |
| EP4412995A1 (en) | 2024-08-14 |
| AU2022360968A1 (en) | 2024-02-29 |
| CA3229067A1 (en) | 2023-04-13 |
| KR20240077491A (ko) | 2024-05-31 |
| CN118019734A (zh) | 2024-05-10 |
| TW202330501A (zh) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024538694A (ja) | シクロペンチルピラゾールｃｄｋ２阻害剤 | |
| EP3112364B1 (en) | 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom | |
| WO2024235286A1 (en) | Tricyclic compounds and uses thereof | |
| KR20130129244A (ko) | 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도 | |
| KR20140020823A (ko) | Ｎａｍｐｔ의 억제를 위한 구아니딘 화합물 및 조성물 | |
| EP4034535B1 (en) | Aza-quinoline compounds and uses thereof | |
| JP2019518059A (ja) | ＰＩ３Ｋβ阻害剤としてのアザベンゾイミダゾール誘導体 | |
| KR102589213B1 (ko) | 피리미딘 사이클로헥세닐 글루코코르티코이드 수용체 조절제 | |
| JP6545262B2 (ja) | Ｒｉｐｋ２阻害剤およびそれを用いた癌の治療方法 | |
| JP2023145547A (ja) | Ｃｄ７３阻害剤、その製造方法と応用 | |
| EP4186905A1 (en) | Compound serving as btk inhibitor, preparation method therefor, and use thereof | |
| JP2020520960A (ja) | アザアリール誘導体、その製造方法および薬学上の応用 | |
| CN112457306A (zh) | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 | |
| CA3145864A1 (en) | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof | |
| JP2019524678A (ja) | ヘッジホッグ経路アンタゴニスト活性を持つキラル複素環式化合物、及びその製造方法、並びに応用 | |
| EP3705480A1 (en) | Class of amino-substituted nitrogen-containing fused ring compounds, preparation method therefor, and use thereof | |
| EP4293029A1 (en) | Azaheteroaryl compound, preparation method therefor, and application thereof | |
| IL301275A (en) | Heterocyclic heteroaryl compounds and their uses | |
| CN118139846A (zh) | 一种egfr小分子抑制剂、含其的药物组合物及其用途 | |
| CN115215862A (zh) | 嘧啶酮化合物及其用途 | |
| CN117659049A (zh) | 取代桥环类抑制剂及其制备方法和应用 | |
| JP2019518032A (ja) | Ｐｉ３ｋ ｂｅｔａ阻害薬としての二環式ピリジン、ピラジンおよびピリミジン誘導体 | |
| JP2024500919A (ja) | 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤 | |
| JP7053654B2 (ja) | ＰＩ３Ｋβ阻害剤としてのキノキサリン及びピリドピラジン誘導体 | |
| EP4168413B1 (en) | N-linked macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251002 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251002 |